High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T

Hussein, Ayman S.

doi:10.1007/s11239-012-0731-9

Cited by 16 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These variants are also rare in African, Chinese, and American Indian populations (Herrmann et al, 2004;Jun et al, 2006). On the other hand, they are common in Arab countries, with frequencies as high as approximately 11% for FV G1691A and 5% for FII G20212A (P < 0.001), as observed by Hussein (2012) in a Palestinian population.…”

Section: Discussionmentioning

confidence: 90%

“…The high frequency of this polymorphism in the Asian countries Japan (40%) and Korea (44%) (Matsuo et al, 2004;Woo et al, 2009) were significantly different from the frequency found in this study (P = 0.003 and P = 0.011, respectively). Among the Arab countries, the frequency of this polymorphism ranges from 7 to 31% (Almawi et al, 2005;Hussein, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of variants that confer risk for venous thromboembolism in an elderly population of northeastern Brazil

Ferreira-Fernandes

Costa²,

Fernandes³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Venous thromboembolism (VTE) is an important cause of morbidity and mortality stemming from cardiovascular disease. It is a multifactorial disease caused by a combination of acquired risk factors, of which advanced age is the most significant, and genetic factors, including the variants FV G1691A, FII G20210A, and MTHFR C677T. We estimated the prevalence of these genomic variants in an elderly population of northeastern Brazil. The study included 188 elderly persons (65-93 years), of which 68 (36.2%) were men and 120 (63.8%) were women. Variants were detected by polymerase chain reaction-3699 FV G1691A, FII G20210A, and MTHFR C677T in the elderly ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 12 (3): 3698-3707 (2013) restriction fragment length polymorphism analysis, and subsequent electrophoresis on an 8% polyacrylamide gel stained with silver nitrate. The study population was in Hardy-Weinberg equilibrium for the 3 loci. Of the individuals analyzed, none carried variants of FV or FII (0%), and 24.7% had the MTHFR C677T polymorphism: 59 subjects (31.4%) were heterozygous (CT) and 17 subjects (9%) were homozygous (TT). Based on the analysis of these particular genes, we conclude that the study population does not present an increased risk for the development of VTE. Faced with a growing aging population worldwide, similar studies in other countries will help in the prevention of VTE in older individuals.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Prevalence of variants that confer risk for venous thromboembolism in an elderly population of northeastern Brazil

Ferreira-Fernandes

Costa²,

Fernandes³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Some previous studies reported a considerable difference between CVD patients and controls (12)(13)(14)(15), while others had no difference (16)(17)(18).…”

Section: Discussionmentioning

confidence: 89%

Statin and MTHFR C677T Polymorphism in Patients with Cardiovascular Diseases

İzmirli¹,

Bacaksız²,

Alptekin³

et al. 2014

Bezmialem Science

View full text Add to dashboard Cite

Objective: Cardiovascular disease (CVD) is the leading cause of death worldwide. The methylenetetrahydrofolate reductase (MTHFR) gene, located on the short (p) arm of chromosome 1 at position 36.3 (1p36.3), might be a possible risk factor for the pharmacogenetics in CVD. A common polymorphism in MTHFR (C677T, Ala→Val) decreases this enzyme activity and increases the homocysteine concentrations, predisposing one to heart disease. Alternatively, statins, cholesterol-reducing agents, are also used to reduce the homocysteine blood concentrations; the aim of the present study was to evaluate how the genotype frequencies of the MTHFR C677T polymorphism, namely rs1801133, change in the cardiovascular system in patients treated with statin. Methods:In this study, the genotype distribution of the MTHFR C677T polymorphism in CVD patients treated with statin (hydrophilic and lipophilic) (n=290) and healthy controls (n=151) was assessed using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results:In this study, a statistically significant difference in genotype frequencies for the MTHFR C677T polymorphism was found between CVD patients treated with statin and controls (p=0.037). Yöntemler: Bu çalışmada, lipofilik ve hidrofilik statinler ile tedavi edilen kardiyovasküler sistem hastalarında (n=290) ve sağlıklı kontrollerde (n=151) MTHFR C677T polimorfizmindeki genotip dağılımları incelenmiştir. Genotipleme, Polimeraz zincir reaksiyonu (PCR) ve restriksiyon parça uzunluk polimorfizm (RFLP) yöntemi ile yapılmıştır. Bulgular: Bu çalışmada, MTHFR C677T polimorfizminin genotip dağılımında statin tedavisi gören kardiyovasküler sistem hastaları ile kontrol grubu arasında istatistiksel olarak anlamlı bir fark gözlenmiştir (p=0,037). ConclusionSonuç: Türk popülasyonunda statin ile tedavi edilen kardiyovasküler sistem hastaları ile MTHFR C677T polimorfizmi arasında istatistiksel olarak anlamlı bir ilişki ilk kez gösterilmiştir.

show abstract

“…in Central Europe. Such a high prevalence of these SNPs cannot be ignored, especially when combined with other pro-thrombotic risk factors -oral contraceptives, immobility, pregnancy, cancer, age, and gender [55][56][57]. Therefore, we postulate that at least MTHFR C677T SNP should be included in genetic screening.…”

Section: Discussionmentioning

confidence: 99%

Methylenetetrahydrofolate reductase polymorphisms as possible risk factors of venous thrombosis – too weak to take care, too frequent to be ignored…

Krejner¹,

Grzela²

2014

View full text Add to dashboard Cite

Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the metabolism of homocysteine. It has been found that an increased concentration of homocysteine in circulating blood (hyperhomocysteinaemia) may lead to blood vessel damage, which may further be associated with higher risk of various cardiovascular disorders, including venous thrombosis (VT). Among various factors identified to be responsible for hyperhomocysteinaemia, an important role is played by the genetically determined decrease of MTHFR enzymatic activity. This decrease may result from several nucleotide polymorphisms (SNPs) of the gene encoding for MTHFR, with the two most important SNP variants: C677T and A1298C. However, the exact role of the mentioned polymorphisms in the pathogenesis of venous thrombosis remains unclear, especially since the results of several studies conducted so far were inconsistent and did not confirm univocally any such direct relationship. In this review the authors aim to explain the reason of such a discrepancy. Moreover, the authors try to answer the question, whether both mentioned polymorphic variants of the MTHFR gene (C677T and A1298C) are in fact considerable risk factors for venous thrombosis. Based on various pro and contra published so far, the authors conclude that polymorphisms of MTHFR, although recognised as rather weak single risk factors of VT, cannot be underestimated and still require our attention.

show abstract

High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T

Cited by 16 publications

References 24 publications

Prevalence of variants that confer risk for venous thromboembolism in an elderly population of northeastern Brazil

Prevalence of variants that confer risk for venous thromboembolism in an elderly population of northeastern Brazil

Statin and MTHFR C677T Polymorphism in Patients with Cardiovascular Diseases

Methylenetetrahydrofolate reductase polymorphisms as possible risk factors of venous thrombosis – too weak to take care, too frequent to be ignored…

Contact Info

Product

Resources

About